University of California San Francisco, San Francisco, USA
Biology and Treatment of Metastatic Breast Cancer Based on Positive Clinical Trials
Hope S. Rugo, MD, is a Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, where she directs Breast Cancer and Clinical Trial Education. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy and supportive care.
Dr. Rugo is a member of the Breast Oncology Program at the UCSF Breast Cancer Center, an investigator in the national multi-center ISPY2 trial, and is the principal investigator of a number of clinical trials. She is one of three recipients of a Komen Promise Award, receives funding from The Breast Cancer Research Foundation, and serves on a number of steering committees for national and international trials. She is a member of the ALLIANCE Breast Core Committee and the Translational Breast Cancer Research Consortium, is the UCSF representative to the NCCN Guidelines Committee, and serves on several committees for the American Society of Clinical Oncology. She has published many peer-reviewed papers and has given presentations on a variety of cancer related topics.
With a summa cum laude degree from Tufts University. Dr. Rugo received her MD from the University of Pennsylvania and completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF, and she completed a postdoctoral fellowship in immunology at Stanford University. She received the Cancer Care physician-of-the-year award in 2010.
Dr Hope Rugo – University of San Francisco Cancer Research Institute, San Francisco, USA
If cancer cells remain after initial treatment, they have a greater likelihood of developing resistance later on in the disease. Using the most effective treatment from the start may help decrease the risk of treatment
resistant cancer cells in the future (Pfizer sponsored).
ecancer is the leading oncology channel committed to improving cancer communication and education with the goal of optimising patient care and outcomes. By using the latest technologies ecancer works closely with leading figures in oncology to inform and educate the global cancer community.